Literature DB >> 9562012

Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia.

B Schwartzkopff1, M Mundhenke, B E Strauer.   

Abstract

OBJECTIVES: The study was designed to investigate the architecture of subendocardial arterioles of patients with hypertrophic cardiomyopathy (HCM) and angina pectoris with respect to coronary vasodilator reserve.
BACKGROUND: There is growing evidence that the coronary microvasculature is abnormal in HCM. Arterioles, which mainly regulate intramyocardial blood flow, are especially suspect.
METHODS: Thirteen patients with HCM (50.1+/-12.6 years old, mean value +/- SD) were studied after exclusion of any relevant coronary stenoses. Subendocardial arterioles (density [n/mm2], wall area [microm2], percent lumen area [%lumen], periarteriolar collagen area [microm2]), myocyte diameter (microm) and interstitial collagen fraction (Vv%) were evaluated by means of stereologic morphometry of transvenous biopsy samples. Coronary blood flow was measured quantitatively with the inert chromatographic argon method at basal conditions and after dipyridamole (0.5 mg/kg body weight over 4 min intravenously), and coronary vasodilator reserve was calculated as the ratio of coronary resistance at basal conditions and after pharmacologic vasodilation. Data from five normotensive subjects (45.4+/-11 years old, p = NS) served as control data.
RESULTS: Arteriolar density was diminished by 38% (p = 0.004) and %lumen by 13% (p = 0.009) in patients with HCM compared with control subjects. Coronary reserve was impaired in patients with HCM (2.28+/-0.6 vs. 5.34+/-1.49, p = 0.003) because of higher coronary resistance after vasodilation (0.48+/-0.14 vs. 0.22+/-0.06 mm Hg x min x 100 g/ml, p = 0.004). Coronary vasodilator reserve correlated with arteriolar density (r = +0.47, p = 0.045) and with %lumen (r = 0.65, p = 0.003).
CONCLUSIONS: In HCM, the architecture of preterminal subendocardial arterioles is altered by a reduced total cross-sectional lumen area, corresponding to an impaired coronary vasodilator capacity that may predispose to myocardial ischemia.

Entities:  

Mesh:

Year:  1998        PMID: 9562012     DOI: 10.1016/s0735-1097(98)00036-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  33 in total

1.  Stress-induced changes in subendocardial tissue texture in hypertrophic cardiomyopathy: an echocardiographic videodensitometric study.

Authors:  A Pingitore; E Picano; M Paterni; M Passera
Journal:  Int J Cardiovasc Imaging       Date:  2001-08       Impact factor: 2.357

2.  Electrocardiographic Characterization of Cardiac Hypertrophy in Mice that Overexpress the ErbB2 Receptor Tyrosine Kinase.

Authors:  Polina Sysa-Shah; Lars L Sørensen; M Roselle Abraham; Kathleen L Gabrielson
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

3.  Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction.

Authors:  M Fassbach; B Schwartzkopff
Journal:  Z Kardiol       Date:  2005-05

4.  Coronary flow reserve in hypertrophic cardiomyopathy: relation with microvascular dysfunction and pathophysiological characteristics.

Authors:  M J Kofflard; M Michels; R Krams; M Kliffen; M L Geleijnse; F J Ten Cate; P W Serruys
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

5.  Functional effects of a tropomyosin mutation linked to FHC contribute to maladaptation during acidosis.

Authors:  Katherine A Sheehan; Grace M Arteaga; Aaron C Hinken; Fernando A Dias; Cibele Ribeiro; David F Wieczorek; R John Solaro; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2010-11-01       Impact factor: 5.000

6.  Systolic compression of epicardial coronary and intramural arteries in children with hypertrophic cardiomyopathy.

Authors:  Saidi A Mohiddin; Lameh Fananapazir
Journal:  Tex Heart Inst J       Date:  2002

Review 7.  Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives.

Authors:  Georgios K Efthimiadis; Efstathios D Pagourelias; Thomas Gossios; Thomas Zegkos
Journal:  World J Cardiol       Date:  2014-02-26

8.  Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Tai Sekine; Masao Daimon; Rei Hasegawa; Kiyomi Teramoto; Takayuki Kawata; Nobuhiro Tanaka; Yasuhiro Takei; Kenji Takazawa; Katsuya Yoshida; Issei Komuro
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

9.  Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy.

Authors:  James M Wilson; Rollo P Villareal; Ramesh Hariharan; Ali Massumi; Raja Muthupillai; Scott D Flamm
Journal:  Tex Heart Inst J       Date:  2002

10.  Assessment of intravascular and extravascular mechanisms of myocardial perfusion abnormalities in obstructive hypertrophic cardiomyopathy by myocardial contrast echocardiography.

Authors:  Osama I I Soliman; Paul Knaapen; Marcel L Geleijnse; Pieter A Dijkmans; Ashraf M Anwar; Attila Nemes; Michelle Michels; Wim B Vletter; Adriaan A Lammertsma; Folkert J ten Cate
Journal:  Heart       Date:  2007-05-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.